Empirical antiviral therapy for suspected viral moderate-severity CAP in adults

For adults with moderate-severity CAP, consider influenza A or B and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) depending on the local epidemiology (eg high rates of community transmission).

Consider adding antiviral therapy for influenza to empirical antibiotic therapy for moderate-severity CAP while awaiting the results of nucleic acid amplification tests (NAAT) (eg polymerase chain reaction [PCR]). For dosage regimens, see Antiviral therapy for influenza.

For links to resources on diagnosis and management of SARS-CoV-2, see Diagnosis and management of COVID-19.